Management of Grade 2 Diastolic Dysfunction

Primary Care Management

The American College of Cardiology recommends managing asymptomatic patients with grade 2 diastolic dysfunction by optimizing control of underlying conditions, such as hypertension and diabetes, as they have excellent outcomes with this approach 1
Blood pressure control is critical, with targets of less than 130/80 mmHg if well-tolerated, and avoiding diastolic pressures below 60 mmHg, particularly in patients with coronary disease 2
The American College of Cardiology suggests initiating ACE inhibitors or ARBs as first-line agents to improve ventricular relaxation and promote regression of left ventricular hypertrophy 3
Adding beta-blockers to control heart rate and increase diastolic filling time is a primary therapeutic goal, according to the American College of Cardiology 3
The American Heart Association recommends using thiazide diuretics judiciously if volume overload is present, but avoiding excessive diuresis, which can reduce cardiac output 2, 3

The American College of Cardiology indicates that cardiology referral is necessary for symptomatic heart failure, despite grade 2 diastolic dysfunction, as this changes management significantly and requires specialist evaluation 4, 1
The American College of Cardiology recommends referring patients with symptomatic or demonstrable myocardial ischemia, as coronary revascularization may be beneficial (Class IIa recommendation) 5, 4, 1
Patients with atrial fibrillation requiring rate control optimization and anticoagulation decisions should be referred to cardiology, according to the American College of Cardiology 4
Inadequate response to primary care management after 3-6 months of optimized blood pressure and heart rate control is an indication for cardiology referral, as per the American College of Cardiology 2

The American College of Cardiology advises against aggressively treating asymptomatic diastolic dysfunction with heart failure medications, as evidence does not support this approach 1
Excessive diuresis should be avoided, as patients with diastolic dysfunction are prone to hypotension and reduced cardiac output with overly aggressive volume reduction, according to the American College of Cardiology 2, 3
The American Heart Association recommends not lowering diastolic blood pressure below 60 mmHg, particularly in elderly patients or those with coronary artery disease, as this can compromise coronary perfusion 2

Baseline echocardiographic assessment should be performed to establish diastolic function parameters, with repeat evaluation within 2-3 months if chronicity is uncertain, as recommended by the American College of Cardiology 1
Ongoing clinical assessment is necessary to detect onset of symptoms, which fundamentally changes the management approach and may trigger cardiology referral, according to the American College of Cardiology 1

Coronary arteries primarily perfuse during diastole; therefore, a reduction in diastolic arterial pressure diminishes the driving pressure for coronary blood flow, especially to the subendocardial layer, which is most vulnerable to ischemia. Evidence level: basic physiological data. 6

In individuals with established coronary artery disease, the Syst‑Eur trial demonstrated increased adverse events when diastolic blood pressure fell below 55–60 mm Hg, indicating that excessively low diastolic pressure can be harmful. Evidence level: randomized controlled trial (RCT). 6
Diastolic pressures under 60–70 mm Hg are associated with compromised myocardial perfusion, particularly in patients who have underlying coronary disease or left‑ventricular hypertrophy, because the reduced perfusion pressure limits oxygen delivery to the myocardium. Evidence level: physiological and clinical observations. 6

A post‑hoc analysis of the SHEP (Systolic Hypertension in the Elderly Program) trial identified a subgroup with diastolic pressures below 60–70 mm Hg that experienced markedly higher cardiovascular risk; the authors interpreted this as likely reflecting greater severity of underlying cardiac disease rather than a direct causal effect of low diastolic pressure. Evidence level: post‑hoc subgroup analysis (moderate). 6
The same Syst‑Eur trial reported that participants with low diastolic blood pressure had higher non‑cardiovascular mortality even when assigned to placebo (i.e., without antihypertensive treatment), supporting the view that low diastolic pressure is a marker of disease severity rather than a direct cause of mortality. Evidence level: RCT placebo arm data (high). 6